Back to search

Article

Efficacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small-Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical Trials

2022-01-17

Abstract excerpt

<h4>Introduction: </h4> Several clinical studies have shown the emergence of immune checkpoint inhibitors (ICIs) could break the standard of care and generate clinical benefits for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC). We aim to assess the efficacy and safety of immuno-based therapy in patients with ES-SCLC. Methods Our search was performed in PubMed, Embase, Cochrane, and Web of Science databases fo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f49d9014-a74e-5ed2-8d5d-eb30c626dd22
DOI
10.21203/rs.3.rs-1200219/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small-Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical TrialsDOI 10.21203/rs.3.rs-1200219/v1
Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in advanced non-small cell lung cancer: A systematic review of randomized controlled trialsSemantic proximity
Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity
Comparative Safety of Immune Checkpoint Inhibitors and Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-AnalysisSemantic proximity
Comparison of efficacy and safety between PD-1 inhibitors and PD- L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysisSemantic proximity
Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis.Semantic proximity
The Predictive efficacy of tumor mutational burden for immune Checkpoint Inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trialsSemantic proximity
Efficacy of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR-mutationsSemantic proximity
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.Semantic proximity
Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.Semantic proximity
Oncological therapy in stage IV lung cancer patients at the end-of-life – A retrospective single-center cohort analysis in the era of tyrosine kinase inhibition and immunotherapySemantic proximity
Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.Semantic proximity
Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world studySemantic proximity
Select a neighboring publication to make it the new centre.